This evidence supports the rationale of our central hypothesis and our findings that liraglutide weakens cardiomyopathy streptozotocin-induced diabetes through the modulation of the ILK and PI3K/AKT/PTEN pathway. The gene discussed is ILK; the disease is cardiomyopathy.